Table 2.
Clinical trials information for adapter CAR T cell therapy in the United States and Europe.
| ClinicalTrials.gov identifier | Study Start/Completion Dates | Phase | Disease | CAR ECD, Adapter | Status |
|---|---|---|---|---|---|
| NCT02776813 | 5/18/16 – 2/20/20 | 1 | CD20+ Non-Hodgkin’s lymphoma | CAR ECD – CD16 (ACT087) Adapter – Rituximab |
Completed |
| NCT03266692 | 2/22/18 – 10/1/19 | 1 | Multiple myeloma | CAR ECD – CD16 (ACT087) Adapter – SEA-BCMA |
Terminated |
| NCT03189836 | 10/4/17 – 9/21/20 | 1 | DLBCL, follicular lymphoma | CAR ECD – CD16 (ACT707) Adapter – Rituximab |
Terminated |
| NCT03680560 | 3/3/19 – 3/12/20 | 1 | Solid tumors overexpressing Her2 | CAR ECD – CD16 (ACT707/ACT087) Adapter – Trastuzumab |
Terminated |
| NCT04450069 | 8/14/20 - | 1 | Relapsed/Refractory B-cell lymphomas | CAR ECD – anti-PNE scFv (CLBR001) Adapter – anti-CD19 fab SWI019 |
Recruiting |
| NCT04230265 | 1/28/20 - | 1 | AML/ALL | CAR ECD – UniCAR02-T Adapter – TM123 (anti-CD123) |
Recruiting |
| NCT04633148 | 11/23/20 - | 1 | PMSA+ solid tumors – CRPC, NSCLC, TNBC | CAR ECD – UniCAR02-T Adapter – TMpPMSA (anti-PMSA) |
Recruiting |